PROCEPT BioRobotics Corp
PROCEPT BioRobotics (Nasdaq: PRCT) develops, manufactures and sells robotic systems for minimally invasive urologic surgery, initially focused on treating benign prostatic hyperplasia (BPH). Its AquaBeam and HYDROS systems deliver Aquablation therapy, which combines imaging, personalized treatment planning, automated… From the company’s description.
Over the twelve months to Sep 30, 2026, PROCEPT BioRobotics Corp reported revenue of $352.31M, up 17.5% from a year earlier, and a net loss of $114.86M. Its operating margin was −33.6%, and operations used $76.69M in cash. In fiscal 2025, it reported revenue of $308.05M, up 37.2% from fiscal 2024, and a net loss of $95.57M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What PROCEPT BioRobotics Corp does
In the company’s own words
PROCEPT BioRobotics (Nasdaq: PRCT) develops, manufactures and sells robotic systems for minimally invasive urologic surgery, initially focused on treating benign prostatic hyperplasia (BPH). Its AquaBeam and HYDROS systems deliver Aquablation therapy, which combines imaging, personalized treatment planning, automated robotics and a heat-free waterjet to remove prostate tissue; each procedure uses a single-use disposable handpiece. Customers include hospitals, as well as ambulatory surgery centers, leasing companies and distribution partners, with sales primarily to hospitals and through a direct sales organization in the United States. International sales use both direct teams and distribution partners. The company’s two systems are the first-generation AquaBeam and the next-generation HYDROS, which includes FirstAssist AI software. PROCEPT began developing AquaBeam in 2009; the system received FDA De Novo approval in 2017, and HYDROS received FDA clearance in 2024. At December 31, 2025, the company had 912 systems installed globally, including 718 in the United States. Revenue was $308.1 million for fiscal 2025. Its website is www.procept-biorobotics.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- SAN JOSE, CA
- Fiscal year end
- December
- CIK
- 1588978
- SIC
- 3841
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns PROCEPT BioRobotics Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · PROCEPT BioRobotics Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do PROCEPT BioRobotics Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of PROCEPT BioRobotics Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in PROCEPT BioRobotics Corp's last four quarterly filings that the numbers alone won't show?”